Cyclerion Therapeutics Inc (CYCN) Actualités

Form 8-K - Current report

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

        – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Proxy Statement - Merger or Acquisition (definitive) (defm14a)

TABLE OF CONTENTS UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Schedule 14AProxy Statement Pursuant to Section 14(a...

Proxy Statement - Merger or Acquisition (preliminary) (prem14a)

TABLE OF CONTENTS UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Schedule 14AProxy Statement Pursuant to Section 14(a) of...

Current Report Filing (8-k)

Exhibit 99.1   Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement...

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the...

Current Report Filing (8-k)

false12-310001755237NASDAQ00017552372023-05-192023-05-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Amended Statement of Beneficial Ownership (sc 13d/a)

    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D (Rule 13d-101)   INFORMA...